BioLife Solutions, Inc. (BLFS): Price and Financial Metrics

BioLife Solutions, Inc. (BLFS)

Today's Latest Price: $28.58 USD

0.43 (1.53%)

Updated Oct 22 4:00pm

Add BLFS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 142 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

BLFS Stock Summary

  • BLFS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 555.27 -- higher than 93.62% of US-listed equities with positive expected earnings growth.
  • Price to trailing twelve month operating cash flow for BLFS is currently 179.31, higher than 97.93% of US stocks with positive operating cash flow.
  • BLFS's price/sales ratio is 24.36; that's higher than the P/S ratio of 93.27% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Biolife Solutions Inc are LLNW, XXII, EPAY, PD, and CNTG.
  • Visit BLFS's SEC page to see the company's official filings. To visit the company's web site, go to

BLFS Stock Price Chart Interactive Chart >

Price chart for BLFS

BLFS Price/Volume Stats

Current price $28.58 52-week high $30.27
Prev. close $28.15 52-week low $7.37
Day low $28.04 Volume 144,500
Day high $28.89 Avg. volume 260,535
50-day MA $25.01 Dividend yield N/A
200-day MA $17.39 Market Cap 914.62M

BioLife Solutions, Inc. (BLFS) Company Bio

BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company was founded in 1987 and is based in Bothell, Washington.

BLFS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$28.58$3.35 -89%

Below please find a table outlining a discounted cash flow forecast for BLFS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Biolife Solutions Inc ranked in the 12th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 88.5%. As for the metrics that stood out in our discounted cash flow analysis of Biolife Solutions Inc, consider:

  • As a business, BLFS is generating more cash flow than merely 6.57% of positive cash flow stocks in the Healthcare.
  • The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 2.09% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Biolife Solutions Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -1,238.5. This coverage rate is greater than that of merely 0.46% of stocks we're observing for the purpose of forecasting via discounted cash flows.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Biolife Solutions Inc? See LGND, ELAN, PCRX, RGEN, and TEVA.

BLFS Latest News Stream

Event/Time News Detail
Loading, please wait...

BLFS Latest Social Stream

Loading social stream, please wait...

View Full BLFS Social Stream

Latest BLFS News From Around the Web

Below are the latest news stories about Biolife Solutions Inc that investors may wish to consider to help them evaluate BLFS as an investment opportunity.

BioLife Solutions: High Volatility And Growth

Strategy requires thought, tactics require observation. – Max Euwe Despite the technological advancement in almost every industry, this pandemic has opened our eyes to the medical field's substantial deficiencies. Funding for innovative treatments and drug discovery are now deemed necessary while these were being debated upon pre-pandemic. This development in...

Michael A. Gayed, CFA on Seeking Alpha | September 28, 2020

BioLife Solutions initiated Buy at Cowen; indicates stock significantly undervalued

BioLife Solutions ([[BLFS]] +5.2%) initiated at Cowen with Outperform, PT $33, indicating the stock is significantly undervalued; currently hovering around 52-week high levels gained 166% in past 6 months trading.Wall Street Analysts Rating is Very Bullish, PT $25.36 has been crossed already by the company.Analyst Chris said that the company is...

Seeking Alpha | September 18, 2020

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...

Benzinga | September 17, 2020

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...

Benzinga | September 16, 2020

The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ...

Benzinga | September 15, 2020

Read More 'BLFS' Stories Here

BLFS Price Returns

1-mo 5.15%
3-mo 46.11%
6-mo 161.96%
1-year 72.38%
3-year 314.20%
5-year 1,199.09%
YTD 76.64%
2019 34.50%
2018 100.50%
2017 272.67%
2016 -25.81%
2015 32.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7152 seconds.